Terumo (4543) Investor Day 2026 summary

Strategic direction and growth initiatives

• Focus on a scalable, repeatable growth model leveraging core technologies and disciplined investment in high-growth areas, with steady progress in growth and profitability.

• Emphasis on innovation, automation, and expanding access globally, particularly in emerging markets like Africa.

• Integration of acquired businesses, such as Organ Technologies, to realize synergies in R&D, manufacturing, and sales.

• Upcoming GS31 announcement in December will outline further strategic priorities and portfolio evolution.

• Enhanced cross-functional collaboration and streamlined decision-making processes to accelerate innovation and development pace.

Business developments and market expansion

• Africa identified as a durable growth engine, with localized hubs, government partnerships, and tailored training programs to drive healthcare access and revenue.

• Organ Technologies forecasts 40% year-on-year revenue growth, driven by increased market penetration and new device launches.

• New generation of organ perfusion devices to target liver and kidney transplant markets, with future expansion into cardiac transplantation.

• CDMO business in Germany aims for large-scale projects, with flexible production lines and a target of 100 billion yen in revenue.

• China recognized as a key growth market for imaging equipment, with plans to optimize product lineup and market entry strategies.

Financial performance and guidance

• Achieved record-high revenue and profit in FY25, with a 5-year company-wide revenue CAGR of 12%.

• FY26 guidance targets 9% YoY revenue growth (8% excluding FX) and 20% operating profit margin, excluding new M&A.

• Organ Technologies expects adjusted operating profit margins to remain at 20%.

• All GS26 financial targets are expected to be achieved, with steady operational improvements enhancing profitability.

• Two M&As executed in FY25 accelerated business expansion and growth.